Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 · The Lancet · 6,440 citations
https://doi.org/10.1016/s0140-6736(15)01281-7
J
José Luis Perez‐Gracia
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
476
Papers
29.3K
Citations
64
h-index
154
i10-index
José Luis Perez‐Gracia is an academic researcher from Navarre Institute of Health Research. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & Cancer Genomics and Diagnostics. The author has an h-index of 64, co-authored 405 publications.
ORCID: 0000-0003-4941-9075Papers by this author
worksProphylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
2019 · Nature · 472 citations
https://doi.org/10.1038/s41586-019-1162-y
Strategies to design clinical studies to identify predictive biomarkers in cancer research
2016 · Cancer Treatment Reviews · 102 citations
https://doi.org/10.1016/j.ctrv.2016.12.005
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
2019 · Annals of Oncology · 102 citations
https://doi.org/10.1093/annonc/mdy545
Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
2009 · British Journal of Cancer · 81 citations
https://doi.org/10.1038/sj.bjc.6605409
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
2009 · Annals of Oncology · 28 citations
https://doi.org/10.1093/annonc/mdp067
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat